Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis Hit By Canakinumab NSCLC Miss

Interleukin-1 Beta Inhibitor Fails To Improve Survival

Mar 09 2021

• By Kevin Grogan

dart — CANOPY-2 misses the target • Source: Shutterstock

Related Content

Wider Than AZ’s PACIFIC – Novartis Has Broad NSCLC Plans For Canakinumab

Nov 15 2017

Novartis’s Canakinumab Fails In COVID-19 Pneumonia Patients

Nov 06 2020

CANTOS: Modest CV And Intriguing Lung Cancer Benefit With Canakinumab

Aug 27 2017

Related Companies

Novartis AG

Merck & Co., Inc.

Additional Topics

Clinical Trials Research & Development Inflammation Cancer BioPharmaceutical

More from Immunological

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.